Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citationDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 6×
“Deleterious effects on blood pressure may contraindicate angiotensin inhibitors for some patients 14,54 .”
InfluentialSelf-citationVakoc, B. J., Lanning, R. M., Tyrrell, J. A., Padera, T. P., Bartlett, L. A., Stylianopoulos, T., Munn, L. L., Tearney, G. J., Fukumura, D., Jain, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.1971 · Cited by 719 · cited 1×
“Optical frequency-domain imaging was carried out after 7 days of treatments using a custom-built microscope 61 .”
Self-citationDuncan, M. R., Frazier, K. S., Abramson, S., Williams, S., Klapper, H., Huang, X., & Grotendorst, G. R. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.13.1774 · Cited by 631
Cell Mechanics: Integrating Cell Responses to Mechanical Stimuli
Janmey, P. A., & McCulloch, C. A. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.151927 · Cited by 630 · cited 2×
“Similarly, angiotensin (1–7), a MAS agonist that can reduce CAF matrix production, may be useful for targeting solid stress 53 .”
Brown, E. B., Campbell, R. B., Tsuzuki, Y., Xu, L., Carmeliet, P., Fukumura, D., & Jain, R. K. (2001) · Nature Medicine · doi:10.1038/89997 · Cited by 605
Self-citationPluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Self-citationDelivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597 · cited 14×
“As hyaluronan synthesis is similarly TGF-b 1 dependent, we expected that losartan would also decrease hyaluronan production.”
InfluentialSelf-citationBardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 581
The renin–angiotensin system and cancer: old dog, new tricks
George, A. J., Thomas, W. G., & Hannan, R. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2945 · Cited by 525 · cited 2×
“Despite the previous classification of angiotensin inhibitors as antiangiogenics 32 , we found that losartan did not reduce vascular endothelial growth factor (VEGF) levels (Supplementary Fig.”
Stylianopoulos, T., Martin, J. D., Snuderl, M., Mpekris, F., Jain, S. R., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4521 · Cited by 477 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationChauhan, V. P., Popović, Z., Chen, O., Cui, J., Fukumura, D., Bawendi, M. G., & Jain, R. K. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201104449 · Cited by 473
Self-citationAngiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism
Habashi, J. P., Doyle, J. J., Holm, T. M., Aziz, H., Schoenhoff, F., Bedja, D., Chen, Y., Modiri, A. N., Judge, D. P., & Dietz, H. C. (2011) · Science · doi:10.1126/science.1192152 · Cited by 472 · cited 1×
“Importantly, this result fits with the known effects of angiotensin signalling on fibrosis in other diseases 29–31 .”
Mori, T., Kawara, S., Shinozaki, M., Hayashi, N., Kakinuma, T., Igarashi, A., Takigawa, M., Nakanishi, T., & Takehara, K. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199910)181:1<153::aid-jcp16>3.0.co;2-k · Cited by 468
Universal GFP reporter for the study of vascular development
Motoike, T., Loughna, S., Perens, E., Roman, B. L., Liao, W., Chau, T. C., Richardson, C. D., Kawate, T., Kuno, J., Weinstein, B. M., et al. (2000) · genesis · doi:10.1002/1526-968x(200010)28:2<75::aid-gene50>3.0.co;2-s · Cited by 451 · cited 1×
“We generated a SMA P -dsRed/Tie2 P -GFP/ FVB double-transgenic mice by crossing Tie2 P -GFP/ FVB mice 59 with a SMA P -dsRed mice 19 .”
Oxygen Gradients in the Microcirculation
TSAI, A. G., JOHNSON, P. C., & INTAGLIETTA, M. (2003) · Physiological Reviews · doi:10.1152/physrev.00034.2002 · Cited by 450
Angiotensin II Type 1a Receptor-deficient Mice with Hypotension and Hyperreninemia
Sugaya, T., Nishimatsu, S.-I., Tanimoto, K., Takimoto, E., Yamagishi, T., Imamura, K., Goto, S., Imaizumi, K., Hisada, Y., Otsuka, A., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18719 · Cited by 366
(1999) · PubMed · Cited by 348
Self-citationRole of host angiotensin II type 1 receptor in tumor angiogenesis and growth
Egami, K., Murohara, T., Shimada, T., Sasaki, K.-I., Shintani, S., Sugaya, T., Ishii, M., Akagi, T., Ikeda, H., Matsuishi, T., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16645 · Cited by 345 · cited 1×
“This is in contrast to the ability of angiotensin signalling through AT1 to promote tumour growth and metastasis 32,37,38,48,49 , with signalling through AT2 hindering growth 50 .”
Liu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330 · cited 1×
“We recently found that the ARB losartan can reduce collagen I production in CAFs by downstream inhibition of transforming growth factor (TGF)- b 1 activation 14,15 through thrombospondin-1 (TSP-1) inhibition 16–18 .”
Self-citationRodríguez-Vita, J., Sánchez-López, E., Esteban, V., Rupérez, M., Egido, J., & Ruiz-Ortega, M. (2005) · Circulation · doi:10.1161/01.cir.0000165133.84978.e2 · Cited by 327
Michel, M. C., Foster, C., Brunner, H. R., & Liu, L. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007278 · Cited by 301 · cited 1×
“…we expect that angiotensin inhibitor distribution into tumours may be the most important factor controlling efficacy: drugs displaying a lack of tissue penetration (such as candesartan) would therefore be poor candidates relative to those with high penetration (such as losartan and telmisartan) 55 .”
Impaired lymphatic contraction associated with immunosuppression
Liao, S., Cheng, G., Conner, D. A., Huang, Y., Kucherlapati, R. S., Munn, L. L., Ruddle, N. H., Jain, R. K., Fukumura, D., & Padera, T. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116152108 · Cited by 296 · cited 8×
“We generated transgenic FVB mice expressing the fluorescent protein dsRed driven by the promoter for a -smooth-muscle actin ( a SMA) 19 , a marker for activated CAFs.”
InfluentialSelf-citationSorensen, A. G., Emblem, K. E., Polaskova, P., Jennings, D., Kim, H., Ancukiewicz, M., Wang, M., Wen, P. Y., Ivy, P., Batchelor, T. T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2464 · Cited by 295 · cited 2×
“Meanwhile, patients with low tumour perfusion— presumably with extensive hypoxia and impaired drug delivery— show poorer chemotherapy responses and shorter survival versus patients with high perfusion 10,11 .”
Self-citationYang, F., Chung, A. C. K., Huang, X. R., & Lan, H. Y. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.136531 · Cited by 258 · cited 1×
“…factor (CCN2/CTGF), a matricellular protein, stabilizes the transient fibrosis produced by TGF-b 1 activity 20,21 and is downstream of angiotensin signalling through TGF-b 1 in other fibrosis diseases 22,23 , suggesting that losartan could be destabilizing the matrix by inhibiting CCN2 expression.”
Thrombospondin1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms
Sweetwyne, M. T., & Murphy-Ullrich, J. E. (2012) · Matrix Biology · doi:10.1016/j.matbio.2012.01.006 · Cited by 241 · cited 1×
“We recently found that the ARB losartan can reduce collagen I production in CAFs by downstream inhibition of transforming growth factor (TGF)- b 1 activation 14,15 through thrombospondin-1 (TSP-1) inhibition 16–18 .”
Suganuma, T., Ino, K., Shibata, K., Kajiyama, H., Nagasaka, T., Mizutani, S., & Kikkawa, F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1946 · Cited by 237 · cited 2×
“This is perhaps because these growth inhibitory effects are primarily seen at much higher doses of ARBs 36,46,51 or with long-term treatment 52 ; indeed, when used at low doses, ARBs have been shown by others to not cause a growth delay 47 .”
Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks
Kamoun, W. S., Chae, S.-S., Lacorre, D. A., Tyrrell, J. A., Mitre, M., Gillissen, M. A., Fukumura, D., Jain, R. K., & Munn, L. L. (2010) · Nature Methods · doi:10.1038/nmeth.1475 · Cited by 214
Self-citationYoshiji, H., Kuriyama, S., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., & Fukui, H. (2001) · PubMed · Cited by 211
Scaling rules for diffusive drug delivery in tumor and normal tissues
Baish, J. W., Stylianopoulos, T., Lanning, R. M., Kamoun, W. S., Fukumura, D., Munn, L. L., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018154108 · Cited by 182 · cited 2×
“Details of the models and corresponding equations are described in Baish et al 34 .”
Self-citationTwo-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors
Alexandrakis, G., Brown, E. B., Tong, R. T., McKee, T. D., Campbell, R. B., Boucher, Y., & Jain, R. K. (2004) · Nature Medicine · doi:10.1038/nm981 · Cited by 178 · cited 1×
“Hyaluronan interacts with collagen in a complex manner 13 , and both contribute to the accumulation of solid stress through these interactions 5 .”
Self-citationReduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins
Chae, Y. K., Valsecchi, M. E., Kim, J., Bianchi, A. L., Khemasuwan, D., Desai, A., & Tester, W. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.616252 · Cited by 174 · cited 1×
“…of retrospective clinical data suggest that the use of AT1 blockers (ARBs) and ACE-Is to manage hypertension in cancer patients receiving standard therapies is correlated with longer survival in pancreatic and other cancers 41–43 , as well as a reduced risk of recurrence in breast cancer 44 .”
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Sasahira, N., Hirano, K., Kogure, H., Kawakubo, K., Yagioka, H., Yashima, Y., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605955 · Cited by 172
Rhodes, D. R., Ateeq, B., Cao, Q., Tomlins, S. A., Mehra, R., Laxman, B., Kalyana-Sundaram, S., Lonigro, R. J., Helgeson, B. E., Bhojani, M. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900351106 · Cited by 172 · cited 1×
“This is perhaps because these growth inhibitory effects are primarily seen at much higher doses of ARBs 36,46,51 or with long-term treatment 52 ; indeed, when used at low doses, ARBs have been shown by others to not cause a growth delay 47 .”
Cheng, T.-H., Cheng, P.-Y., Shih, N.-L., Chen, I.-B., Wang, D. L., & Chen, J.-J. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.06.010 · Cited by 163
Wilop, S., von Hobe, S., Crysandt, M., Esser, A., Osieka, R., & Jost, E. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0587-3 · Cited by 163 · cited 1×
“…of retrospective clinical data suggest that the use of AT1 blockers (ARBs) and ACE-Is to manage hypertension in cancer patients receiving standard therapies is correlated with longer survival in pancreatic and other cancers 41–43 , as well as a reduced risk of recurrence in breast cancer 44 .”
Shi-Wen, X., Rodríguez-Pascual, F., Lamas, S., Holmes, A., Howat, S., Pearson, J. D., Dashwood, M. R., du Bois, R. M., Denton, C. P., Black, C. M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00625-06 · Cited by 156
Fujita, M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh324 · Cited by 156 · cited 1×
“AT1 signalling has been shown to increase VEGF expression by CAFs 45 , and both ACE-Is and ARBs can decrease VEGF expression and angiogenesis 46,47 been assumed that their indirect antiangiogenic properties, through downstream VEGF inhibition, benefit survival additively.”
Naito, T., Masaki, T., Nikolic-Paterson, D. J., Tanji, C., Yorioka, N., & Kohno, N. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00139.2003 · Cited by 156
Park, M.-S., Klotz, E., Kim, M.-J., Song, S. Y., Park, S. W., Cha, S.-W., Lim, J. S., Seong, J., Chung, J. B., & Kim, K. W. (2009) · Radiology · doi:10.1148/radiol.2493080226 · Cited by 142
Targeting the TGFβ, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma
Leask, A. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.01.006 · Cited by 137
Keizman, D., Huang, P., Eisenberger, M. A., Pili, R., Kim, J. J., Antonarakis, E. S., Hammers, H., & Carducci, M. A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.019 · Cited by 126 · cited 1×
“…of retrospective clinical data suggest that the use of AT1 blockers (ARBs) and ACE-Is to manage hypertension in cancer patients receiving standard therapies is correlated with longer survival in pancreatic and other cancers 41–43 , as well as a reduced risk of recurrence in breast cancer 44 .”
Self-citationAngiotensin II Facilitates Breast Cancer Cell Migration and Metastasis
Rodrigues, S., Abdelkarim, M., Dillenburg-Pilla, P., Luissint, A., Tommaso, A. D., Deshayes, F., Pontes, C. L. S., Molina, A., Cagnard, N., Letourneur, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035667 · Cited by 118 · cited 2×
“This is in contrast to the ability of angiotensin signalling through AT1 to promote tumour growth and metastasis 32,37,38,48,49 , with signalling through AT2 hindering growth 50 .”
Greco, S., Muscella, A., Elia, M. G., Salvatore, P., Storelli, C., Mazzotta, A., Manca, C., & Marsigliante, S. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10313 · Cited by 115 · cited 1×
“This is in contrast to the ability of angiotensin signalling through AT1 to promote tumour growth and metastasis 32,37,38,48,49 , with signalling through AT2 hindering growth 50 .”
Angiotensin-(1-7) Reduces Fibrosis in Orthotopic Breast Tumors
Cook, K. L., Metheny-Barlow, L. J., Tallant, E. A., & Gallagher, P. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1136 · Cited by 92 · cited 1×
“Similarly, angiotensin (1–7), a MAS agonist that can reduce CAF matrix production, may be useful for targeting solid stress 53 .”
Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis
Nabeshima, Y., Tazuma, S., Kanno, K., Hyogo, H., Iwai, M., Horiuchi, M., & Chayama, K. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.183 · Cited by 88
Arnold, S. A., Rivera, L. B., Carbon, J. G., Toombs, J. E., Chang, C.-L., Bradshaw, A. D., & Brekken, R. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031384 · Cited by 77 · cited 9×
“S21), consistent with previous studies 36 and probably because of the role of angiotensin signalling in promoting the metastatic cascade 37,38 .”
InfluentialDoi, C., Egashira, N., Kawabata, A., Maurya, D. K., Ohta, N., Uppalapati, D., Ayuzawa, R., Pickel, L., Isayama, Y., Troyer, D. L., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-67 · Cited by 72 · cited 1×
“This is in contrast to the ability of angiotensin signalling through AT1 to promote tumour growth and metastasis 32,37,38,48,49 , with signalling through AT2 hindering growth 50 .”
Hama, K., Ohnishi, H., Yasuda, H., Ueda, N., Mashima, H., Satoh, Y., Hanatsuka, K., Kita, H., Ōhashi, A., Tamada, K., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.155 · Cited by 57 · cited 1×
“As the effects of losartan on matrix expression in tumours were pronounced, and as angiotensin signalling has been previously shown to activate fibroblasts in other fibrosis diseases 24,25 , we next tested whether losartan could also reduce CAF density.”
Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Takahara, N., Ito, Y., Matsubara, S., Uchino, R., Yagioka, H., Arizumi, T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9972-5 · Cited by 51 · cited 2×
“Indeed, the inadequate tumour penetration of candesartan may explain why it only improved chemotherapy outcomes modestly, when comparing high versus low candesartan doses, in a recent pancreatic cancer study 54 .”
Yoshiji (2009) · Oncology Reports · doi:10.3892/or_00000445 · Cited by 48 · cited 1×
“This is perhaps because these growth inhibitory effects are primarily seen at much higher doses of ARBs 36,46,51 or with long-term treatment 52 ; indeed, when used at low doses, ARBs have been shown by others to not cause a growth delay 47 .”
Protective role of angiotensin II type 2 receptor signaling in a mouse model of pancreatic fibrosis
Ulmasov, B., Xu, Z., Tetri, L. H., Inagami, T., & Neuschwander-Tetri, B. A. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90409.2008 · Cited by 40
Amano, H., Ito, Y., Ogawa, F., Eshima, K., Suzuki, T., Oba, K., Matsui, Y., Kato, S., Fukui, T., Nakamura, M., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.10.026 · Cited by 37 · cited 2×
“This is in contrast to the ability of angiotensin signalling through AT1 to promote tumour growth and metastasis 32,37,38,48,49 , with signalling through AT2 hindering growth 50 .”
Liu, W. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i41.6489 · Cited by 34 · cited 1×
“As the effects of losartan on matrix expression in tumours were pronounced, and as angiotensin signalling has been previously shown to activate fibroblasts in other fibrosis diseases 24,25 , we next tested whether losartan could also reduce CAF density.”
McCarthy, N. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2996 · Cited by 16
Cited by
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Self-citationDelivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
“This vaccine is capable of eliminating CAFs by stimulating a CD8 + T Diverse CAF-targeted depleting immunotherapeutic strategies in preclinical/clinical studies FAP fibroblast activation protein, DC dendritic cell, shA20 A20-specific shRNA, TRP2 tyrosine-related protein 2, AdC68 adenoviral vector of chimpanzee serotyp…”
BackgroundInfluentialElyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
“An inhibitor of this receptor, Losartan, was shown to reduce intratumoral solid stress, leading to increased vascular perfusion and improved drug delivery (48, 78).”
Background
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.